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Abstract
Background—The contribution of immune activation to accelerated HIV-disease progression in
older individuals has not been delineated.
Methods—Prospective multicenter cohort of older (≥45 years) and younger (18–30 years) HIV-
infected adults initiating 192 weeks of antiretroviral therapy (ART). Longitudinal models of CD4
cell restoration examined associations with age-group, thymic volume, immune activation, and
viral load.
Results—Forty-five older and 45 younger adults (median age 50 and 26 years, respectively)
were studied. Older patients had fewer naive CD4 cells (P <0.001) and higher HLA-DR/CD38
expression on CD4 (P = 0.05) and CD8 cells (P = 0.07) than younger patients at any time on ART.
The rate of naive and total CD4 cell increase was similar between age groups, but older patients
had a faster mean rate of B-cell increase (by +0.7 cells/week; P = 0.01), to higher counts than
healthy controls after 192 weeks (P = 0.003). Naive CD4 increases from baseline were associated
with immune activation reductions (as declines from baseline of %CD8 cells expressing HLA-DR/
CD38; P <0.0001), but these increases were attenuated in older patients, or in those with small
thymuses. A 15% reduction in activation was associated with naive gains of 29.9 and 6.2 cells/μl
in younger, versus older patients, or with gains of 25.7, 23.4, and 2.1 cells/μl in patients with the
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largest, intermediate, and smallest thymuses, respectively (P <0.01 for interactions between
activation reduction and age-group or thymic volume).
Conclusion—Older patients had significant B-cell expansion, higher levels of immune
activation markers, and significantly attenuated naive CD4 cell gains associated with activation
reduction.
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Introduction
Older age at the time of HIV-1 infection is a strong predictor of accelerated HIV disease
progression in the absence of antiretroviral therapy (ART) [1], and older age (>45 years)
upon ART initiation is an independent predictor of AIDS or death [2–5]. Older adults (age
>50) have a reduced capacity to restore naive and total CD4 cells with ART, despite often
better adherence [6–8], and superior HIV-1 viral load suppression compared to younger
individuals [6,9,10]. Older persons also have reduced thymopoiesis [11–13], and they are
more likely to present for initial HIV care with lower CD4 cell counts, and each of these is
associated with reduced capacity to restore CD4 cells [14–17].
Immune activation is thought central to HIV disease pathogenesis [18,19]. It is associated
with reduced CD4 cell restoration on ART [20–22], and with increased morbidity and
mortality, both in HIV disease and in the general population [23–25]. Contributions of
immune activation to reduced CD4 cell restoration in older persons have not been
delineated.
ACTG 5015 is a prospective multicenter cohort study of older (age ≥45 years) and younger
(age 18–30 years) ART-naive adults, to explore the immunologic basis of age-associated
accelerated HIV disease progression. Participants began a uniform ART regimen and
underwent intensive immunologic monitoring. Baseline and week 48 observations from this
cohort were previously reported [26,27].
We hypothesized that differences in immune activation contribute to reduced CD4 cell
restoration capacity in older HIV-infected individuals on ART. To test this hypothesis we
examined age-associated differences of activation markers [%CD8 cells that express HLA-
DR/CD38, and soluble plasma tumor necrosis factor receptor (sTNFR)-2], which we
compared with simultaneously enrolled, age-matched healthy controls (ACTG 5113).
Independent contributions of age group, thymic volume, immune activation (as changes in
%CD8 cells that expressed HLA-DR/CD38), and viral load suppression were explored in
longitudinal linear models of naive, memory, and total CD4 cell changes from baseline on
ART.
Methods
ACTG 5015 is a multicenter, prospective study of older (≥45 years) and younger (18–30
years) HIV-1-infected, ART-naive adults who enrolled between 2000 and 2004. All
participants began stavudine, emtricitabine, and lopinavir/ritonaivir, and were followed up to
192 weeks. New diagnoses of hypertension, diabetes, and cardiovascular events (myocardial
infarction, angina, congestive heart failure, peripheral vascular disease) were prespecified.
Observations from patients who permanently discontinued ART, or who initiated
chemotherapy, or prednisone were censored. The institutional review boards at each site
approved this study, and all participants gave written informed consent to participate.
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Virologic and immunologic studies
Lymphocyte subsets were enumerated in freshly obtained whole blood by three-color flow
cytometry using the AACTG consensus immunology protocol [28]; naive cells were defined
as CD45RA+/CD62L+; memory cells were CD45RO+/CD45RA−; B cells were CD19+ and
natural killer (NK) cells were CD3−/CD16+/CD56+.
The first 55 patients participated in an immunology substudy (ACTG 5016s) that also
included thymic volume measurements, plasma cytokines (TNF-α, sTNFR-2, interleukin-7),
and vaccination with tetanus toxoid (Aventis Pasteur, Swiftwater, Pennsylvania; Lederle-
Praxis, West Henrietta, New York; or Wyeth-Ayerst, Philadelphia, Pennsylvania, USA)
among all substudy participants, and hepatitis A vaccine (Smith-Kline Beecham, King of
Prussia, Pennsylvania, USA), among hepatitis A antibody-negative participants at baseline
and week 24. Age-matched healthy volunteers were simultaneously enrolled into ACTG
study 5113 for cross-sectional comparisons. They underwent similar immunologic
measurements, but received only one dose of each vaccine at baseline [26]. Serum
antibodies to vaccine antigens were measured at baseline and week 12 for all participants,
and also at week 36 for HIV-infected patients. Thymic volumes were estimated by
noncontrast chest computed tomography (CT) scans at baseline, weeks 24 and 144, and
scored on a scale of 0–5, as previously described [12]. Scores were categorized within
tertiles of approximately equal numbers of patients, defined as small (scores 0–1, n = 18),
intermediate (score 2, n = 19), and large (scores 3–5, n = 18).
Statistical analysis
Cox proportional hazard models examined association between age group and time to viral
load rebound among patients who achieved suppression to less than 200 copies/ml within 24
weeks of ART initiation. Rebound was defined as a confirmed viral load above 200 copies/
ml after initial suppression. Age group differences of each immunologic index was assessed
in separate mixed-effects models adjusted for sex, self-reported race (black, non-black), and
time-varying viral loads; models of CD8 cell subsets, B cells, and cytokines were also
adjusted for baseline CD4 cell counts.
Mixed-effects models of naive, memory, and total CD4 cell restoration examined
associations with immune activation, thymic volume, and viral load replication. Covariate in
these models either included age group or thymic volume, and included baseline viral load,
time-varying viral load suppression (as viral load <50, 50 to 1000, and ≥1000 copies/ml),
and immune activation changes from baseline (as %CD8 cells that expressed HLA-DR/
CD38). Immune activation changes were centered (each value was subtracted from the study
population mean after 192 weeks, then divided by the SD). Models were adjusted for sex
and race and they tested interactions between age group or thymic volume, with activation
reduction and with viral load suppression. They assumed an autoregressive covariance
structure and used random intercepts and random slopes.
The stratified (by sex) Wilcoxon Rank-Sum test was used to compare immune indices
between HIV-infected patients and healthy controls within each age group, using the last
protocol-specified measurement for HIV-infected patients; shift parameters and confidence
intervals (CIs) were obtained by inverting this test. The generalized Cochran–Mantel–
Haenszel test (also stratified by sex) compared week 48 thymic volume tertiles between
HIV-infected patients and controls. Statistical significance was defined as P less than 0.05
and no adjustment was made to account for multiple testing in these secondary, exploratory
analyses. All analyses were performed using SAS (version 9.1; SAS Institute, Cary, North
Carolina, USA).
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Age group differences in clinical and virologic outcomes in HIV-infected patients
Fifty-nine (66%) of 90 participants completed 192 weeks of follow-up, including 31 of 45
(69%) older, and 28 of 45 (62%) younger patients (P = 0.66). Older patients had more new
cardiovascular events (P = 0.049), and tended to have more new diagnoses of diabetes (P =
0.24), and AIDS-defining events or deaths (P = 0.14) (Table 1). There were no significant
age group differences in the proportion of patients who achieved initial viral load
suppression to below 200 copies/ml, but younger patients had a higher risk of viral load
rebound after initial suppression [initial viral load suppression: 38 of 45 (84%) older versus
37 of 45 (82%) younger; rebound 6 older versus 16 younger; P = 0.02].
Thirty-one patients (17 younger and 14 older) prematurely withdrew from this study, among
whom 16 younger, and seven older patients either were lost to follow-up, withdrew consent,
or indicated that they were unable to return for study visits; one younger and seven older
patients withdrew because they had met a prespecified indication for study discontinuation,
were too debilitated to continue, or died. There was no statistically significant difference
between age groups at the time to study discontinuation.
Age group differences in the slopes of immunologic indices among HIV-infected patients
Older HIV-infected patients had a significantly faster mean rate of B-cell increase [by +0.7
cells/μl per week of ART (95% CI 0.2–1.3 cells/μl per week), P = 0.01], and a significantly
faster mean rate of increase in the %CD4 cells that expressed CD28 [by +0.04% per week
(95% CI 0.01–0.08%), P = 0.009] compared to younger patients (Fig. 1, Table 2 and
Supplemental Table, http://links.lww.com/QAD/A322). Older patients also had a
significantly slower rate of hepatitis A antibody increase after vaccination [by −0.014 mIU/
ml per week (−0.025 to −0.002 mIU/ml per week), P = 0.02]. There were no significant age
group differences in the slopes of other immunologic indices.
Age group differences in the main effects of immunologic indices among HIV-infected
participants
Older patients maintained significantly fewer naive and total CD4 cells (P ≤ 0.03), they had
a trend towards fewer naive CD8 cells (P = 0.053), but they had more NK cells (P = 0.03)
than younger patients, as determined by the main effects of age group in each model (where
the main effect is an estimate of the vertical distance between two approximately parallel
lines, henceforth described as the differences at any time on ART; Fig. 1, Table 2 and
Supplemental Table, http://links.lww.com/QAD/A322). Older patients also had a
significantly lower %CD8 cells that expressed CD28 (P = 0.002) and significantly smaller
thymuses (P = 0.001), while having significantly higher %CD4 and %CD8 cells that
expressed CD95/Fas (P <0.003), and a trend towards higher HLA-DR/CD38 expression on
these cells (P = 0.054 and 0.07, respectively). Although plasma TNF-α concentrations
(measured to week 48) did not differ between the age groups, plasma sTNFR-2
concentrations were significantly higher in older patients (P = 0.006).
Comparisons between HIV-infected, and HIV-uninfected participants
After 192 weeks of ART, older and younger HIV-infected patients both had significantly
fewer total CD4 cells (P ≤ 0.02), significantly more naive, memory and total CD8 cells (P
<0.02), significantly higher %CD4 and %CD8 cells that expressed HLA-DR/CD38 (P
<0.001) compared to age-matched, HIV-uninfected healthy controls (Fig. 1, Table 2 and
Supplemental Table, http://links.lww.com/QAD/A322). HIV-infected patients in both age
groups also had significantly lower tetanus antibody concentrations 12 weeks after the first
vaccination (at weeks 0) than controls, and despite similar plasma TNF-α levels, they also
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had higher plasma sTNFR-2 concentrations after 48 weeks of ART (P <0.001). After 192
weeks of ART, NK cell counts and the %CD4 and %CD8 cells that expressed CD95/Fas
were similar between HIV-infected patients and controls in both age groups.
HIV-infected older, but not younger patients had significantly fewer naive (P <0.001) and
memory CD4 cells after 192 weeks (P = 0.04), significantly more B cells (P = 0.003), and
significantly higher hepatitis A antibody concentrations than their corresponding age-
matched controls after the first vaccination (P = 0.01). In contrast, younger HIV-infected
patients had significantly lower %CD4 and %CD8 cells that expressed CD28 compared to
controls after 192 weeks (P ≤ 0.01), whereas these differences were reduced to trends among
older patients (P = 0.07 and P = 0.06 for %CD4 and %CD8 cells, respectively). Younger
HIV-infected patients also had trends towards smaller thymuses (measured to week 144; P =
0.09) and higher IL-7 plasma concentrations (measured to week 48; P = 0.096) than
controls, but these indices did not differ significantly among older patients.
Multivariable models of naive cell restoration on antiretroviral therapy, and antibody
responses to vaccination
In longitudinal models, the magnitude of naive CD4 cell increase from baseline was
independently associated with time-varying viral load suppression (as <50, 50 to 1000, and
>1000 copies/ml; P = 0.02), and with the magnitude of immune activation reduction (as
time-varying changes from baseline in the %CD8 cells that expressed HLA-DR/CD38; P
<0.001). The latter association depended on age, however, so the naive cell increases
associated with activation reduction were significantly attenuated in older patients (Table 3).
A 15% reduction in activation was associated with naive CD4 increases from baseline of
29.9 cells/μl in younger patients, versus 6.2 cells/μl in older patients (P <0.001 for the
interaction between activation reduction and age group). A similar interaction was evident
when baseline thymic volume replaced age group, where this magnitude of activation
reduction was associated with naive CD4 cell gains of 25.7, 23.4, and 2.1 cells/μl in patients
with the largest, intermediate, and smallest thymic volumes, respectively (P = 0.007 for the
interaction between activation reduction and thymic volume).
Interactions with immune activation were evident when age was treated as a continuous
variable (data not shown), and they persisted in models of naive CD4 cell restoration that
were stratified by baseline CD4 cell counts (P = 0.004 and P = 0.03 for interactions with
thymic volumes in patients with <200, and ≥200 baseline CD4 cell counts, respectively).
Significant interactions with age group or thymic volume were not detected with
associations between naive CD4 increases and viral load suppression (P = 0.35 and P = 0.48,
respectively).
Memory CD4 cell changes were associated with immune activation reductions (P = 0.003),
but not viral load suppression (P = 0.23), and significant interactions were evident between
activation reduction and age group (P = 0.0002), but not between activation reduction and
thymic volume (P = 0.20) in these models. Viral load suppression and activation reduction
also were associated with total CD4 cell increases (P = 0.004 and P <0.0001, respectively),
and interactions were detected between activation reduction and age group, or thymic
volume (P = 0.02 and P = 0.06, respectively) in these models.
Discussion
In this prospective, age-differentiated cohort study, older patients had fewer naive and total
CD4 cells, higher plasma sTNFR-2 concentrations, and they had trends towards higher
HLA-DR/CD38 expression on CD4 and CD8 cells compared to younger patients at any time
on ART. Older patients also exhibited a faster average rate of B-cell increase on ART, to
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counts that were significantly higher than age-matched healthy controls despite similar rates
of naive, memory, and total CD4 cell increases between the age groups, and they had more
NK cells at any time on ART. Consistent with previous studies, reductions in immune
activation (defined as changes in the %CD8 cells expressing HLA-DR/CD38) were
associated with naive, memory, and total CD4 cell increases [20,22], but these associated
increases were significantly attenuated in older patients, or in those with small thymuses,
extending previous observations from this cohort of a similar interaction in association with
early naive CD4 cell changes on ART [27].
Interactions between age and immune activation may imply qualitative differences in CD4
cells, or thymic function according to age, including increased CD4 cell susceptibility to
activation-induced cell death in older patients. Homeostatic proliferation is a process by
which naive CD4 cells undergo post-thymic expansion while retaining most of their
phenotypic and functional naive cell characteristics [29]. Younger HIV-infected adults on
ART have higher co-expression of CD31, a marker of recent thymic emigration on naive
CD4 cells, than older adults [13]. Although thymic volume by CT cannot distinguish
thymopoietically active epithelial space from inactive perivascular space within the thymus
[30], thymic volume measured this way has previously been associated with naive CD4 cell
increases in ART-treated HIV-infected adults [31]. Further study is warranted to determine
whether naive CD4 cell restoration via homeostatic, versus intrathymic production pathways
of naive may account for the interactions that we observed between immune activation and
thymic volume. It is also possible that these interactions may identify a general impairment
of CD4 cell restoration capacity in older persons that is not specifically related to immune
activation mechanisms since older patients also had lower CD4 cell responses associated
with viral load suppression. Even though significant interactions were not detected between
age group, or thymic volume in these associations with viral load suppression, insufficient
statistical power could have accounted for our inability to detect such interactions.
Older patients had a significantly slower rate of hepatitis A antibody increase after
vaccination, but unexpectedly they had higher hepatitis A antibody concentrations compared
to healthy older controls after the first vaccination. Previous studies identified B-cell
activation markers as predictors of AIDS-associated lymphomas, AIDS-defining infections,
or death [23,28,32], implicating possible contributions of B-cell activation to HIV-disease
pathogenesis. Further study is warranted to better understand the implications of the age-
associated differences in B-cell expansion that we observed.
Common immune perturbations that are characteristic of both untreated HIV-disease and
normal aging [33], combined with the premature incidence of some age-associated
morbidities support a hypothesis of premature aging in HIV disease [34,35]. Included
among these perturbations are reduced T-cell receptor repertoire via diminished thymic
output with lower circulating naive T-cell counts [12,36], expansion of senescent CD8+ T
cells (defined by CD28−/CD57+) [37,38], and macrophage dysfunction [39]. Differences
between HIV-infected patients and controls that were accentuated among younger patients
in the present study included lower CD28 expression on CD8 cells, smaller thymuses, and
higher plasma IL-7 levels that may indicate premature immunosenescence.
Older patients experienced more cardiovascular events in this cohort. Although these events
were not independently adjudicated, they were collected prospectively according to
protocol-specified definitions. Also consistent with several other studies, we previously
reported that medication adherence was better in older patients, which may have accounted
for the lower rate of viral load rebound that we observed in older patients [40].
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A strength of this study was in the prospective, protocol-specified measurement of selected
immunologic indices in association with a uniform ART regimen, among ART-naïve
patients, that were compared with simultaneously enrolled, age-matched healthy controls.
Consistent with observations from the North American-ACCORD where older persons had
lower CD4 cell counts at first presentation for HIV care [17], we previously reported
significantly lower baseline CD4 cell counts in older HIV-infected patients [26]. Because
the age at HIV-1 infection is unknown, we cannot exclude bias by confounding from more
advanced HIV disease to have influenced the age group differences in this study. Since
interactions between immune activation and age also were evident in separate models of
naive CD4 cell restoration that were stratified by baseline CD4 cell counts (as <200, and
≥200 cells/μl), confounding by advanced HIV disease is unlikely to have influenced these
interactions.
Although we previously reported no significant age group differences in grade 3 or 4
medication-associated toxicities [40], it is possible that stavudine use may have contributed
to a greater risk of mitochondrial dysfunction in older patients since age is a strong risk
factor for nucleoside analog-associated lipodystrophy [41], a complication that has been
associated with reduced mitochondrial (mt)DNA content [42]. Previous studies have
identified significant differences in mtDNA according to prior nucleoside analog exposure
[43]. Differences between mtDNA haplogroups also were associated with the magnitude of
CD4 restoration [44], and with differences in T-cell activation on ART (as CD38/HLA-DR
expression on CD4 and CD8 cells) [45], implicating possible contributions by mitochondrial
function to the association between CD4 cell restoration and immune activation.
Only 64% of participants completed 192 weeks of follow-up in this study and this high
attrition rate reduced the power to detect age group differences. Despite similar dropout
rates between the age groups, missing data from attrition are a potential source of bias as the
reasons for study discontinuation appeared to differ between the age groups, with higher
attrition due to illness among older patients. Finally, statistical significance for all
comparisons was not adjusted for multiple testing, hence these comparisons should be
considered exploratory.
In conclusion, older HIV-infected patients maintained higher levels of some immune
activation markers, and they demonstrated significant B-cell expansion on ART. Age and
thymic volume modified associations between immune activation and CD4 cell restoration,
so older patients had significantly attenuated naive, memory and total CD4 cell increases in
association with activation reduction, and naive cell gains that were associated with
activation reduction also were attenuated in patients with small thymuses. These interactions
may identify qualitative differences in CD4 cells or thymic function according to age that
warrant further study.
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Fig. 1. Changes in immune indices with ART in older and younger subjects
(a and b) Changes in mean naive and memory CD4 cell counts; (c and d) naive and memory
CD8 cells, (e) B cells, (f) NK cells, (g and h) %CD4+ and CD8+ cells expressing HLA-DR/
CD38 cells, (i and j) %CD4+ and CD8+ cells expressing CD28, (k and l) %CD4+ and CD8+
cells expressing CD95, (m) soluble tumor necrosis receptor plasma concentration, (n)
Kalayjian et al. Page 11













plasma interleukin 7 levels, and (o) hepatitis A and tetanus antibody concentrations after
vaccination, in older (solid line) and young (broken line) over time among HIV-infected
patients (left panels) compared with healthy HIV-uninfected controls (right panels). Vertical
lines represent 1 SD from the mean.
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Table 1





 Hypertension 5 2
 Peripheral vascular disease 2 0
 Heart disease 2 0
Total 9 2
Diabetes 3 0 0.24
HIV-associated or death 0.14
 Pneumocystis jorovecci 1 0
 Cryptococcal meningitis 0 1
 Toxoplasmic encephalitis 0 1
 AIDS wasting 1 0
 Esophageal candidiasis 1 1
 HIV-associated myelopathy 1 0
 Non Hodgkin’s lymphoma 1 1
 HIV-associated nephropathy 1 0
 Anogenital neoplasia 1 0
 Othera 1 0
 Death 2 0
Total 10 4
a
Central nervous system mass lesion of undetermined cause.
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Table 2
A summary of age group differences among HIV-infected patients and differences between HIV-infected
patients and healthy controls.
HIV+: older versus younger HIV+ versus healthy control
Baseline Week 0 to 192 Older Younger
Naive CD4 cells ↓ ↓ ↓ ↔
Naive CD8 cells ↓ ↓* ↑ ↑
Memory CD4 cells ↔ ↔ ↓ ↔
Memory CD8 cells ↑* ↑* ↑ ↑
Total CD4 cells ↓ ↓ ↓ ↓
Total CD8 cells ↔ ↔ ↑ ↑
B cells ↓ ▲ ↑ ↔
NK cells ↔ ↑ ↔ ↔
%CD4 expressing CD28 ↓* ▲ ↓* ↓
%CD8 expressing CD28 ↓ ↓ ↓* ↓
%CD4 expressing HLA-DR/CD38 ↔ ↑* ↑ ↑
%CD8 expressing HLA-DR/CD38 ↔ ↑* ↑ ↑
%CD4 expressing CD95 ↑ ↑ ↔ ↔
%CD8 expressing CD95 ↑ ↑ ↔ ↔
TNF-α ↔ ↔ ↔ ↔
sTNFR-2 ↑ ↑ ↑ ↑
IL7 ↔ ↔ ↔ ↑*
Thymic CT score ↓ ↓ ↔ ↓*
Vaccine response hepatitis A ▼ ↑ ↔
Vaccine response tetanus ↔ ↓ ↓
‘▲’ or ‘▼’ identify significant slope differences (P <0.05) between HIV-infected older and younger patients, by mixed-effects linear models; ‘↓’ or
‘↑’ identify significant differences (P <0.05) in the main-effects of age-group, or differences between HIV-infected patients (at the last protocol-
specified measurement on ART) and controls by shift parameters. Trends (0.05 ≤ P <0.10) are indicated by an ‘*’, and ‘↔’ indicates no significant
difference (P ≥ 0.10). Baseline age-group differences were previously reported. [26,27].
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Table 3
Estimates of naive and memory CD4 cell increases from baseline in association with immune activation
reduction (as time varying changes from baseline in %CD8+/HLA-DR+/CD38+ cells) and viral load (VL)
suppression (as time-varying plasma VL < 50, 5–0–1000 and >1000 copies/ml), according to age groups or
thymic volume tertiles (as thymic score: 0 to 1, 2, and >2, from CT estimates of thymic volume) from
longitudinal mixed linear models that were adjusted for sex, and race (black, not black).
Naive CD4 cells Memory CD4 cells
P P
Activation reduction × age group <0.001 <0.001
 Younger 29.9 (18.9, 40.9) 25.9 (15.1, 36.8)
 Older 6.2 (−1.0,13.3) −0.4 (−11.6, 10.8)
Activation reduction × thymic volume 0.007 0.20
 Thymic score: >2 25.7 (14.4, 36.9) 15.1 (4.7, 25,5)
 Thymic score: 2 23.4 (−11.4, 35.4) 22.0 (−3.4, 40.5)
 Thymic score: 0–1 2.1 (−10.2, 14.3) 2.4 (−13.3, 18.1)
VL suppression × age group 0.35
 Younger: <50 copies/ml 37.8 (3.7, 71.8)
 Older: <50 copies/ml 15.3 (−1.6, 32.3)
 Younger: 50–1000 copies/ml 30.7 (0.2, 61.2)
 Older: 50–1000 copies/ml 5.5 (−9.7, 20.7)
 versus >1000 copies/ml of the corresponding age group
VL suppression × thymic volume 0.48
 Thymic score >2: <50 copies/ml 29.5 (−3.2, 62.3)
 Thymic score 2: <50 copies/ml 18.5 (−21.6, 58.7)
 Thymic score 0–1: <50 copies/ml 34.9 (15.3, 54.6)
 Thymic score >2: 50–1000 copies/ml 28.4 (1.9, 54.8)
 Thymic score 2: 50–1000 copies/ml 15.0 (−22.3, 52.3)
 Thymic score 0–1: 50–1000 copies/ml 10.1 (−5.9, 26.1)
 versus >1000 copies/ml of the corresponding thymic score category
P-values report the significance of the interaction terms between age group or thymic volume, in the associations between immune activation or VL
suppression with CD4 cell increases. Memory CD4 cell increases were not associated with VL suppression.
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